First-Dose Pharmacokinetics of Lithium Carbonate in Children and Adolescents
Year: 2010
Type: article
Abstract: This study examines the pharmacokinetics of oral doses of lithium carbonate immediate-release capsules after administration of 600 or 900 mg in children and adolescents with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, bipolar I disorder. Lithium plasma concentrations were followed over 48 to 72 hours in 39 subjects (20 male and 19 female subjects; ages, 7-17 years) with mixed or manic episodes enrolled at 7 clinical sites participating in the Collaborative Lithium Trials. Population pharmacokinetic modeling was performed using NONMEM, and influences of patient covariates on pharmacokinetics parameters were examined. The pharmacokinetics of lithium was best described using a 2-compartment model with a lag time and first-order absorption. There was considerable variability in lithium exposures. Lithium clearance related best to fat-free mass. Inclusion of fat-free mass as a covariate reduced the between-subject variability from 52% to 42%. Lithium clearances did not vary systematically with age group, dose, sex, or creatinine clearances. Allometrically scaled clearance and volume of distribution from the population analysis were within the range reported in adults. Single-dose profiles of lithium in young patients with BP-1 show marked variability. Therefore, ongoing serum monitoring is needed during continued therapy. The developed population pharmacokinetic model may be used to predict other dosage regimens, support scaling from adult to pediatric pharmacokinetics, and support the design of future clinical trials.
Institutions: Cincinnati Children's Hospital Medical Center, University Hospitals Cleveland Medical Center, Case Western Reserve University, Eunice Kennedy Shriver National Institute of Child Health and Human Development, University at Buffalo, State University of New York, Northwell Health, Feinstein Institute for Medical Research, University of Illinois Chicago, University of Washington, University of Massachusetts Chan Medical School, University of North Carolina at Chapel Hill
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: U.S. Department of Health and Human Services, American Foundation for Suicide Prevention, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Deutsches Krebsforschungszentrum, National Alliance for Research on Schizophrenia and Depression, Supernus Pharmaceuticals, Otsuka America, H. Lundbeck A/S, National Institutes of Health, U.S. Public Health Service, National Institute of Mental Health, National Institute of Child Health and Human Development, National Center for Research Resources, Janssen Pharmaceuticals, Eunice Kennedy Shriver National Institute of Child Health and Human Development
OpenAlex ID: W1975527302